BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35351858)

  • 1. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.
    Li Y; Gan Y; Liu J; Li J; Zhou Z; Tian R; Sun R; Liu J; Xiao Q; Li Y; Lu P; Peng Y; Peng Y; Shu G; Yin G
    Signal Transduct Target Ther; 2022 Mar; 7(1):87. PubMed ID: 35351858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression.
    Shi L; Hong X; Ba L; He X; Xiong Y; Ding Q; Yang S; Peng G
    Cell Death Dis; 2019 Feb; 10(3):150. PubMed ID: 30770796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.
    Deng X; Kong F; Li S; Jiang H; Dong L; Xu X; Zhang X; Yuan H; Xu Y; Chu Y; Peng H; Guan M
    Cell Death Dis; 2021 May; 12(5):485. PubMed ID: 33986248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Noncoding RNA DLX6-AS1 Regulates the Growth and Aggressiveness of Colorectal Cancer Cells Via Mediating the miR-26a/EZH2 Axis.
    Kong WQ; Liang JJ; Du J; Ye ZX; Gao P; Liang YL
    Cancer Biother Radiopharm; 2021 Nov; 36(9):753-764. PubMed ID: 32379493
    [No Abstract]   [Full Text] [Related]  

  • 5. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 6. The oncogenic role of LncRNA FAM83C-AS1 in colorectal cancer development by epigenetically inhibits SEMA3F via stabilizing EZH2.
    Xue W; Wang F; Han P; Liu Y; Zhang B; Gu X; Wang Y; Li M; Zhao Y; Cui B
    Aging (Albany NY); 2020 Oct; 12(20):20396-20412. PubMed ID: 33109776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA ZNF674-AS1 antagonizes oxaliplatin resistance of gastric cancer via regulating EZH2-mediated methylation of CHST7.
    Ye K; Wang Y
    Aging (Albany NY); 2022 Jul; 14(13):5523-5536. PubMed ID: 35802620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
    Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
    Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsa_circ_0071589 promotes carcinogenesis via the miR-600/EZH2 axis in colorectal cancer.
    Yong W; Zhuoqi X; Baocheng W; Dongsheng Z; Chuan Z; Yueming S
    Biomed Pharmacother; 2018 Jun; 102():1188-1194. PubMed ID: 29710537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ELFN1-AS1 accelerates the proliferation and migration of colorectal cancer via regulation of miR-4644/TRIM44 axis.
    Lei R; Feng L; Hong D
    Cancer Biomark; 2020; 27(4):433-443. PubMed ID: 31929141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
    Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
    Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
    Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
    Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hotair mediates tumorigenesis through recruiting EZH2 in colorectal cancer.
    Huang KB; Zhang SP; Zhu YJ; Guo CH; Yang M; Liu J; Xia LG; Zhang JF
    J Cell Biochem; 2019 Apr; 120(4):6071-6077. PubMed ID: 30362162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.
    Xu TP; Wang WY; Ma P; Shuai Y; Zhao K; Wang YF; Li W; Xia R; Chen WM; Zhang EB; Shu YQ
    Oncogene; 2018 Sep; 37(36):5020-5036. PubMed ID: 29789713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-506-3p inhibits colorectal cancer cell proliferation through targeting enhancer of zeste homologue 2.
    Ai L; Luo X; Yan X; Jiang S
    Bioengineered; 2021 Dec; 12(1):4044-4053. PubMed ID: 34288823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOX9-activated PXN-AS1 promotes the tumorigenesis of glioblastoma by EZH2-mediated methylation of DKK1.
    Chen H; Hou G; Yang J; Chen W; Guo L; Mao Q; Ge J; Zhang X
    J Cell Mol Med; 2020 Jun; 24(11):6070-6082. PubMed ID: 32329150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer.
    Li X; Xing J; Wang H; Yu E
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30038060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1.
    Luo W; Li X; Song Z; Zhu X; Zhao S
    Aging (Albany NY); 2019 Jun; 11(11):3811-3823. PubMed ID: 31186379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.